肝硬化心肌病的研究进展

毛 萱1¹, 韩 雪1¹, 纪文 静2²
1、1.新疆医科大学第二临床医学院 新疆乌鲁木齐 830000 2.新疆医科大学第二附属医院 新疆乌鲁木齐 830000
2、

摘要

摘要：目的：肝硬化心肌病是指肝硬化患者在没有其他明显心脏疾病的情况下，出现心脏结构和功能异常的一种心脏疾病。肝硬化心肌病的发病机制
与多种因素有关，包括心脏血流动力学改变、缺氧、代谢紊乱、炎症反应、自由基损伤以及内分泌紊乱等；心脏影像学诊断技术的发展为肝硬
化心肌病的早期诊断提供了新的手段；目前尚无特效治疗方法，肝移植可以显著改善患者的心脏功能，此外，积极控制肝功能不全和门静脉高
压等并发症，可以减轻症状、延缓疾病进展。

关键词

关键词：肝硬化心肌病；诊断；治疗

参考

[1]徐强, 方玮, 孙高亚, et al. 肝硬化心肌病诊断与治疗研究进

展 [J]. 肝脏, 2022, 27(03): 267-70.

[2]徐小元, 丁惠国, 李文刚, et al. 肝硬化诊治指南 [J]. 实用肝

脏病杂志, 2019, 22(06): 770-86.

[3]WIESE S, HOVE J D, BENDTSEN F, et al. Cirrhotic

cardiomyopathy: pathogenesis and clinical relevance [J]. Nature Reviews

Gastroenterology & Hepatology, 2014, 11(3): 177-86.

[4]ISAAK A, PRAKTIKNJO M, JANSEN C, et al. Myocardial

Fibrosis and Inflammation in Liver Cirrhosis: MRI Study of the

Liver-Heart Axis [J]. Radiology, 2020, 297(1): 51-61.

[5]LEAL-ALVARADO T M, ESCALANTE-SANDOVAL I,

GALVEZ-ROMERO J L, et al. Physiopathological and diagnostic aspects

of cirrhotic cardiomyopathy [J]. Archivos de cardiologia de Mexico, 2020,

90(2): 169-77.

[6]YOON K T, LIU H, LEE S S. Cirrhotic Cardiomyopathy [J].

Current gastroenterology reports, 2020, 22(9): 45-.

[7]MATYAS C, ERDELYI K, TROJNAR E, et al. Interplay of

Liver-Heart Inflammatory Axis and Cannabinoid 2 Receptor Signaling in

an Experimental Model of Hepatic Cardiomyopathy [J]. Hepatology, 2020,

71(4): 1391-407.

[8]LIU H, GASKARI S A, LEE S S. Cardiac and vascular changes in

cirrhosis: Pathogenic mechanisms [J]. World Journal of Gastroenterology,

2006, 12(6): 837-42.

[9]ABBAS W A, AHMED S M K, AAL A M A, et al. Galactin-3 and

brain natriuretic peptide versus conventional echocardiography in the

early detection of cirrhotic cardiomyopathy [J]. Turkish Journal of

Gastroenterology, 2016, 27(4): 367-74.

[10]KOSHY A N, GOW P J, TESTRO A, et al. Relationship between

QT interval prolongation and structural abnormalities in cirrhotic

cardiomyopathy: A change in the current paradigm [J]. American Journal

of Transplantation, 2021, 21(6): 2240-5.

[11]徐强, 方玮, 孙高亚, et al. 肝硬化心肌病诊断与治疗的研

究进展 [J]. 肝脏, 2022, 27(04): 391-4.

[12]MOLLER S, HOVE J D. Cirrhotic cardiomyopathy: Toward an

optimized definition [J]. Liver Transplantation, 2022, 28(8): 1283-4.

[13]KWON H M, MOON Y J, KIM K S, et al. Prognostic Value of

B-Type Natriuretic Peptide in Liver Transplant Patients: Implication in

Posttransplant Mortality [J]. Hepatology, 2021, 74(1): 336-50.

[14]KAPOOR N, MEHTA V, SINGH B, et al. Prevalence of cirrhotic

cardiomyopathy and its relationshipwith serum pro-brain natriuretic

peptide, hepatorenal syndrome, spontaneous bacterial peritonitis, and

mortality [J]. Indian journal of gastroenterology : official journal of the

Indian Society of Gastroenterology, 2020, 39(5): 481-6.

[15]MOON Y-J, KWON H-M, JUNG K-W, et al. Preoperative

high-sensitivity troponin I and B-type natriuretic peptide, alone and in

combination, for risk stratification of mortality after liver transplantation

[J]. Korean Journal of Anesthesiology, 2021, 74(3): 242-53.

[16]ARAUJO T, VOHRA I, PALACIOS P, et al. B-type natriuretic

peptide (BNP) predicts 90-day mortality and need for paracentesis in

cirrhotic patients without systolic heart failure [J]. Scientific Reports,

2021, 11(1).

[17]LYNGBAKKEN M N, AAGAARD E N, KVISVIK B, et al.

Cardiac Troponin I and T Are Associated with Left Ventricular Function

and Structure: Data from the Akershus Cardiac Examination 1950 Study

[J]. Clinical Chemistry, 2020, 66(4): 567-78.

[18]IZZY M, VANWAGNER L B, LIN G, et al. Redefining Cirrhotic

Cardiomyopathy for the Modern Era [J]. Hepatology, 2020, 71(1):

334-45.

[19]SHAH R V, CHEN-TOURNOUX A A, PICARD M H, et al.

Galectin-3, cardiac structure and function, and long-term mortality in

patients with acutely decompensated heart failure [J]. European Journal

of Heart Failure, 2010, 12(8): 826-32.

[20]EMDIN M, AIMO A, VERGARO G, et al. sST2 Predicts

Outcome in Chronic Heart Failure Beyond N-proBNP and

High-Sensitivity Troponin T [J]. Journal of the American College of

Cardiology, 2018, 72(19): 2309-20.

[21]SONNY A, IBRAHIM A, SCHUSTER A, et al. Impact and

persistence of cirrhotic cardiomyopathy after liver transplantation [J].

Clinical Transplantation, 2016, 30(9): 986-93.

[22]SILVESTRE O M, FARIAS A Q, RAMOS D S, et al.

beta-Blocker therapy for cirrhotic cardiomyopathy: a

randomized-controlled trial [J]. European Journal of Gastroenterology &

Hepatology, 2018, 30(8): 930-7.

[23]PREMKUMAR M, RANGEGOWDA D, VYAS T, et al.

Carvedilol Combined With Ivabradine Improves Left Ventricular

Diastolic Dysfunction, Clinical Progression, and Survival in Cirrhosis [J].

Journal of Clinical Gastroenterology, 2020, 54(6): 561-8.

[24]赵敏竹, 杨晋辉, 李玉婷. 肝硬化心肌病的病理特征、发病

机制及诊疗进展 [J]. 山东医药, 2022, 62(22): 91-4.